$NBIO NEWS: ACCESSWIRE / March 8, 2022 / Sharp Hea
Post# of 9163
(Total Views: 141)
Posted On: 03/08/2022 8:33:41 AM
$NBIO NEWS: ACCESSWIRE / March 8, 2022 / Sharp HealthCare, in collaboration with Nascent Biotech, Inc, announced today, its participation in a clinical trial for a novel investigational immunotherapy treatment for patients with glioblastoma (GBM), the deadliest form of brain cancer.
Pritumumab (PTB) is a unique monoclonal antibody that attacks cancers originating in the cells lining an organ - referred to as epithelial cells. These include cancers of the brain, breast, colon and pancreas, as well as melanoma. Prior Phase I and II clinical trials in Japan focused on the treatment of high-grade gliomas including GBM.
This Phase I clinical trial leverages Sharp HealthCare's comprehensive cancer program in this collaboration when treating all forms of brain tumors. With more than 23,000 new cases of GBM diagnosed in the U.S. every year, Sharp HealthCare's cancer expertise and reputation appealed to Nascent Biotech as they chose additional sites.
"The clinical trial is a good fit for Sharp HealthCare, which is devoted to compassionate patient-centered care, creative innovation, and clinical excellence," said Dr. Charles Redfern, medical director of neuro-oncology at Sharp HealthCare's Laurel Amtower Cancer Institute and Neuro-Oncology Center, "This is an exciting clinical trial with targeted immunotherapy for patients with GBM."
Pritumumab (PTB) is a unique monoclonal antibody that attacks cancers originating in the cells lining an organ - referred to as epithelial cells. These include cancers of the brain, breast, colon and pancreas, as well as melanoma. Prior Phase I and II clinical trials in Japan focused on the treatment of high-grade gliomas including GBM.
This Phase I clinical trial leverages Sharp HealthCare's comprehensive cancer program in this collaboration when treating all forms of brain tumors. With more than 23,000 new cases of GBM diagnosed in the U.S. every year, Sharp HealthCare's cancer expertise and reputation appealed to Nascent Biotech as they chose additional sites.
"The clinical trial is a good fit for Sharp HealthCare, which is devoted to compassionate patient-centered care, creative innovation, and clinical excellence," said Dr. Charles Redfern, medical director of neuro-oncology at Sharp HealthCare's Laurel Amtower Cancer Institute and Neuro-Oncology Center, "This is an exciting clinical trial with targeted immunotherapy for patients with GBM."
(0)
(0)Scroll down for more posts ▼